| Quality assessment | No of patients | Effect | Quality | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Best supportive care | Control | Relative (95% CI) | Absolute | |
| Overall survival (mortality rate at follow-up) | |||||||||||
| 11 | randomised trials | none | none | none | serious2 | none | 103/117 (88%) | - | Median OS = 4.6 months | ⊕⊕⊕○ MODERATE | |
| Progression-free survival | |||||||||||
| 11 | randomised trials | none | none | none | serious2 | none | N=117 | - | Median PFS = 1.5 months | ⊕⊕⊕○ MODERATE | |
| Overall tumour response (assessed with: RECIST) | |||||||||||
| 11 | randomised trials | none | none | none | serious2 | none | 0/117 (0%) | - | - | - | ⊕⊕⊕○ MODERATE |
| Grade 3-4 Neutropenia (assessed with: NCI- CTC) | |||||||||||
| 11 | randomised trials | none | none | none | serious2 | none | 1/117 (0.85%) | - | - | - | ⊕⊕⊕○ MODERATE |
| Grade 3-4 Thrombocytopenia (assessed with: NCI-CTC) | |||||||||||
| 11 | randomised trials | none | none | none | serious2 | none | 1/117 (0.85%) | - | - | - | ⊕⊕⊕○ MODERATE |
| Grade 3-4 Anaemia (assessed with: NCI-CTC) | |||||||||||
| 11 | randomised trials | none | none | none | serious2 | none | 9/117 (7.7%) | - | - | - | ⊕⊕⊕○ MODERATE |
| Health-related quality of life | |||||||||||
| 11 | randomised trials | none | none | none | serious2 | none | -3 | - | - | - | ⊕⊕⊕○ MODERATE |
Low number of events reduces precision of this outcome;
Mean scores not reported. There was a continuous decrement in quality of life scores from baseline through week 18. 24% receieved at least one palliative radiotherapy treatment
From: 5, Managing locally advanced or metastatic bladder cancer
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.